AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector
For well over a decade now, the major focus in Alzheimer’s R&D has been concentrating heavily — though not exclusively — on the tangles of toxic amyloid beta and tau that are often associated with the disease. Alector set out to do things differently, though, with a focus on the innate immune response in the brain. Now as investigators for the little biotech aim for the clinic, AbbVie wants in, paying a whopping $205 million in cash — with $20 million reserved for an upcoming round — and promising an undisclosed multiple in milestones to partner on the work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
